Viewing data from:

EXEMESTANE

ANDA

EXEMESTANE | A077431 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Exemestane (2023)

Total Spending

$43.3M

Total Claims

194,259

Beneficiaries

49,951

Avg Cost/Unit

$3.63

Spending Trend

$58.5M(2019)→$54.0M(2020)→$47.8M(2021)→$49.3M(2022)→$43.3M(2023)

YoY Change:-16.1%

5yr CAGR:-11.2%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain10 active DMFs8 inactive

10 active API suppliers hold Drug Master Files for this ingredient.

CURIA SPAIN SAUEXEMESTANE

DMF 178132004

SCINOPHARM TAIWAN LTDEXEMESTANE USP

DMF 211752007

CIPLA LTDEXEMESTANE USP

DMF 220992008

STERLING SPAEXEMESTANE

DMF 224392009

SYMBIOTICA SPECIALITY INGREDIENTS SDN BHDEXEMESTANE

DMF 252752011

SHANDONG ANHONG PHARMACEUTICAL CO LTDEXEMESTANE (NON-STERILE, API)

DMF 260612012

FARMABIOS SPAEXEMESTANE MICRONIZED USP

DMF 262912012

SUN PHARMACEUTICAL INDUSTRIES LTDEXEMESTANE USP

DMF 289602015

CORAL DRUGS PVT LTDEXEMESTANE

DMF 382472023

ZYDUS LIFESCIENCES LTDEXEMESTANE USP

DMF 392822023

PERRIGO API LTDInactiveEXEMESTANE

DMF 202192007

YANCHENG XINYI PHARM AND CHEM CO LTDInactiveEXEMESTANE (NON-STERILE, BULK FORM)

DMF 214412007

TRIFARMA SPAInactiveEXEMESTANE

DMF 223652008

ZYFINE DIV CADILA HEALTHCARE LTDInactiveEXEMESTANE

DMF 225782009

DR REDDYS LABORATORIES LTDInactiveEXEMESTANE

DMF 226452009

QILU PHARMACEUTICAL CO LTDInactiveEXEMESTANE (NON STERILE API)

DMF 235082010

MAC CHEM PRODUCTS INDIA PVT LTDInactiveEXEMESTANE

DMF 269112013

APOTEX PHARMACHEM INDIA PVT LTDInactiveEXEMESTANE

DMF 271672013

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 4, 2011	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 25MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Apr 1, 2011

No patent or exclusivity listings for this strength.